Amphastar Pharmaceuticals AMPH Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $719.89M-1.7% | $731.97M+13.6% | $644.4M+29.1% | $498.99M+14.0% | ||
| $363.83M+1.6% | $358.11M+22.1% | $293.27M+17.3% | $250.13M+5.1% | ||
| $356.06M-4.8% | $373.86M+6.5% | $351.12M+41.1% | $248.86M+24.6% | ||
| 49.5%-1.6pp | 51.1%-3.4pp | 54.5%+4.6pp | 49.9%+4.2pp | ||
| $85.84M+16.1% | $73.91M+0.2% | $73.74M-1.4% | $74.77M+22.7% | ||
| $43.89M+16.1% | $37.8M+31.0% | $28.85M+34.0% | $21.53M+23.1% | ||
| $85.93M+51.5% | $56.72M+10.1% | $51.54M+14.4% | $45.06M-12.4% | ||
| $215.65M+28.0% | $168.44M+9.3% | $154.13M+9.0% | $141.36M+8.9% | ||
| $215.65M+28.0% | $168.44M+9.3% | $154.13M+9.0% | $141.36M+8.9% | ||
| $140.4M-31.7% | $205.42M+4.3% | $196.99M+83.2% | $107.5M+53.8% | ||
| 19.5%-8.6pp | 28.1%-2.5pp | 30.6%+9.0pp | 21.5%+5.6pp | ||
| $25.48M-16.0% | $30.34M+11.7% | $27.16M+1,371% | $1.85M+109% | ||
| $8.68M-18.2% | $10.61M+94.4% | $5.46M+313% | $1.32M+120% | ||
| -$16.78M-7.2% | -$15.66M+38.9% | -$25.63M-400% | $8.54M-40.1% | ||
| $123.62M-34.9% | $189.76M+10.7% | $171.36M+47.7% | $116.04M+37.9% | ||
| $25.53M-14.0% | $29.67M-6.8% | $31.83M+35.6% | $23.48M+13.8% | ||
| $98.09M-38.5% | $159.52M+16.0% | $137.55M+50.5% | $91.39M+47.1% | ||
| 13.6%-8.2pp | 21.8%+0.4pp | 21.3%+3.0pp | 18.3%+4.1pp | ||
| $2.03-33.7% | $3.06+18.1% | $2.59+48.0% | $1.75+40.0% | ||
| $2.10-36.2% | $3.29+15.8% | $2.84+51.9% | $1.87+43.8% | ||
| 193.9M-7.2% | 209M-1.4% | 212M+0.7% | 210.4M+5.8% | ||
| 187.8M-3.3% | 194.2M+0.4% | 193.4M-0.6% | 194.5M+1.8% | ||
| $23K-99.4% | $4.08M+204% | -$3.93M-143% | $9.07M-37.6% | ||
| $140.4M-31.7% | $205.42M+4.3% | $196.99M+83.2% | $107.5M+53.8% | ||
| $197.1M-23.7% | $258.39M+9.9% | $235.02M+77.7% | $132.27M+42.0% | ||
| $197.1M-23.7% | $258.39M+9.9% | $235.02M+77.7% | $132.27M+42.0% | ||
| 27.4%-7.9pp | 35.3%-1.2pp | 36.5%+10.0pp | 26.5%+5.2pp | ||
| $140.4M-31.7% | $205.42M+4.3% | $196.99M+83.2% | $107.5M+53.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amphastar Pharmaceuticals's revenue?
- Amphastar Pharmaceuticals (AMPH) generated $720.5M in revenue over the trailing twelve months, down 1.4% year over year.
- Is Amphastar Pharmaceuticals profitable?
- Amphastar Pharmaceuticals reported $79.2M in net income over the trailing twelve months, a 11.0% net margin.
- What are Amphastar Pharmaceuticals's profit margins?
- Gross margin is 47.3% and operating margin is 16.2%, with a 11.0% net margin.
- What is Amphastar Pharmaceuticals's earnings per share?
- Amphastar Pharmaceuticals's diluted EPS over the trailing twelve months is $1.66.
- Where does Amphastar Pharmaceuticals's income statement data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
